A Proof of Concept Clinical Trial to Investigate OTL-300 in Transfusion-Dependent Beta-Thalassemia Patients
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2019
Price : $35 *
At a glance
- Drugs OTL 300 (Primary) ; Thiotepa; Treosulfan
- Indications Beta-thalassaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 29 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be featured in an oral presentation at the 22nd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C. The presentation will report the updated safety and efficacy results of OTL-300 in nine TDT patients.
- 29 Apr 2019 Results published in the Orchard Therapeutics media release.
- 15 Apr 2019 According to the Orchard Therapeutics media release, data from this trial will be published online in an abstract via the American Society of Gene & Cell Therapy website and full data set will be featured in an oral presentation at the 22nd ASGCT Annual Meeting 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History